References
- Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998;392:245–52.
- Rice AM, Jones KL, Hart DNJ. Dendritic cell preparations fortherapy. Cytotherapy 2004;6:99— 104.
- Nestle FO, Banchereau J, Hart D. Dendritic cells: on the movefrom bench to bedside. Nature Med 2001;7:761–5.
- Barratt-Boyes SM, Figdor CG. Current issues in delivering dendritic cells for immunotherapy. Cytotherapy 2004;6:105–10.
- Figdor CG, de Vries IJM, Lesterhuis WJ, Melief CJM. Dendriticcell immunotherapy: mapping the way. Nature Med 2004;10:475— 80.
- De Vries 1J, Krooshoop DJ, Scharenborg NM et al. Effective migration of antigen-pulsed dendritic cells to lymph nodes in melanoma patients is determined by their maturation state. Cancer Res 2003;63:12— 7.
- Wakkach A, Fournier N, Brun V et al. Characterization of dendritic cells that induce tolerance and T regulatory 1 cell differentiation in vivo. Immunity 2003;18:605— 17.
- Mahnke K, Schmitt E, Bonifaz L et al. Immature, but not inactive: the tolerogenic function of immature dendritic cells. Immunol Cell Biol 2002;80:477–83.
- Dietz AB, Bulur PA, Erickson MR et al. Optimizing preparationof normal dendritic cells and licr-abl± mature dendritic cells derived from immunomagnetically purified CD14± cells. .7 Hematother Stem Cell Res 2000;9:95— 101.
- Dietz AB, Litzow MR, Gastineau DA, Vuk-Pavlovk S. En-gineering dendritic cell grafts for clinical trials in cellular immunotherapy of cancer: example of CML. Croat Med .7 2001;42:428–35.
- Padley DJ, Dietz AB, Gastineau DA, Vuk-Pavlovié S. Mature myeloid dendritic cells for clinical use prepared from CD14± cells isolated by immunomagnetic adsorption. 7 Hematother Stem Cell Res 2001;10: 427–9.
- Boczkowski D, Nair SK, Nam JH et al. Induction of tumor immunity and cytotoxic T lymphocyte responses using dendritic cells transfected with messenger RNA amplified from tumor cells. Cancer Res 2000;60:1028— 34.
- Jonuleit H, Giesecke-Tuettenberg A, Tuting T et al. A comparison of two types of dendritic cell as adjuvants for the induction of melanoma-specific T-cell responses in humans following intranodal injection. Int 7 Cancer 2001;92:243–51.
- Dhodapkar MV, Krasovsky J, Steinman RM, Bhardwaj N. Mature dendritic cells boost functionally superior CD8± T-cells in humans without foreign helper epitopes. 7 Clin Investig 2000;105:R9— 14.
- Babatz J, Roellig C, Oelschlagael U et al. Large-scale immuno-magnetic selection of CD14± monocytes to generate dendritic cells for cancer immunotherapy: a phase I study. 7 Hematother Stem Cell Res 2003;12: 515–23.
- Felzmann T, Witt V, Wimmer D et al. Monocyte enrichment from leukapharesis products for the generation of dendritic cells by plastic adherence, or by positive or negative selection. Cytotherapy 2003;5:391 —8.
- Geiger JD, Hutchinson RJ, Hohenkirk LF et al. Vaccination ofpediatric solid tumor patients with tumor lysate-pulsed den-dritic cells can expand specific T cells and mediate tumor regression. Cancer Res 2001;61:8513— 9.
- Chaperot L, Chokri M, Jacob MC et al. Differentiation of antigen-presenting cells (dendritic cells and macrophages) for therapeutic application in patients with lymphoma. Leukemia 2000;14:1667–77.
- Mu LJ, Gaudernack G, Saeboe-Larrsen S et al. A protocol for generation of clinical grade mRNA-transfected monocyte-derived dendritic cells for cancer vaccines. Scand 7 Immunol 2003;58:578— 86.